Your browser doesn't support javascript.
loading
State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019.
Hasin, Deborah S; Wall, Melanie M; Choi, C Jean; Alschuler, Daniel M; Malte, Carol; Olfson, Mark; Keyes, Katherine M; Gradus, Jaimie L; Cerdá, Magdalena; Maynard, Charles C; Keyhani, Salomeh; Martins, Silvia S; Fink, David S; Livne, Ofir; Mannes, Zachary; Sherman, Scott; Saxon, Andrew J.
Afiliação
  • Hasin DS; Columbia University and New York State Psychiatric Institute, New York.
  • Wall MM; Columbia University and New York State Psychiatric Institute, New York.
  • Choi CJ; Mental Health Data Science, New York State Psychiatric Institute, New York.
  • Alschuler DM; Mental Health Data Science, New York State Psychiatric Institute, New York.
  • Malte C; Health Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, Seattle, Washington.
  • Olfson M; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington.
  • Keyes KM; Columbia University and New York State Psychiatric Institute, New York.
  • Gradus JL; Columbia University, New York, New York.
  • Cerdá M; Boston University, Boston, Massachusetts.
  • Maynard CC; New York University, New York.
  • Keyhani S; VA Puget Sound Health Care System and University of Washington, Seattle, Washington.
  • Martins SS; San Francisco VA Health System and University of California at San Francisco, San Francisco.
  • Fink DS; Columbia University, New York, New York.
  • Livne O; New York State Psychiatric Institute, New York.
  • Mannes Z; Columbia University, New York, New York.
  • Sherman S; Columbia University, New York, New York.
  • Saxon AJ; VA Manhattan Harbor Healthcare and New York University, New York.
JAMA Psychiatry ; 80(4): 380-388, 2023 04 01.
Article em En | MEDLINE | ID: mdl-36857036
ABSTRACT
Importance Cannabis use disorder (CUD) is increasing among US adults. Few national studies have addressed the role of medical cannabis laws (MCLs) and recreational cannabis laws (RCLs) in these increases, particularly in patient populations with high rates of CUD risk factors.

Objective:

To quantify the role of MCL and RCL enactment in the increases in diagnosed CUD prevalence among Veterans Health Administration (VHA) patients from 2005 to 2019. Design, Setting, and

Participants:

Staggered-adoption difference-in-difference analyses were used to estimate the role of MCL and RCL in the increases in prevalence of CUD diagnoses, fitting a linear binomial regression model with fixed effects for state, categorical year, time-varying cannabis law status, state-level sociodemographic covariates, and patient age group, sex, and race and ethnicity. Patients aged 18 to 75 years with 1 or more VHA primary care, emergency department, or mental health visit and no hospice/palliative care within a given calendar year were included. Time-varying yearly state control covariates were state/year rates from American Community Survey data percentage male, Black, Hispanic, White, 18 years or older, unemployed, income below poverty threshold, and yearly median household income. Analysis took place between February to December 2022. Main Outcomes and

Measures:

As preplanned, International Classification of Diseases, Clinical Modification, ninth and tenth revisions, CUD diagnoses from electronic health records were analyzed.

Results:

The number of individuals analyzed ranged from 3 234 382 in 2005 to 4 579 994 in 2019. Patients were largely male (94.1% in 2005 and 89.0% in 2019) and White (75.0% in 2005 and 66.6% in 2019), with a mean (SD) age of 57.0 [14.4] years. From 2005 to 2019, adjusted CUD prevalences increased from 1.38% to 2.25% in states with no cannabis laws (no CLs), 1.38% to 2.54% in MCL-only enacting states, and 1.39% to 2.56% in RCL-enacting states. Difference-in-difference results indicated that MCL-only enactment was associated with a 0.05% (0.05-0.06) absolute increase in CUD prevalence, ie, that 4.7% of the total increase in CUD prevalence in MCL-only enacting states could be attributed to MCLs, while RCL enactment was associated with a 1.12% (95% CI, 0.10-0.13) absolute increase in CUD prevalence, ie, that 9.8% of the total increase in CUD prevalence in RCL-enacting states could be attributed to RCLs. The role of RCL in the increases in CUD prevalence was greatest in patients aged 65 to 75 years, with an absolute increase of 0.15% (95% CI, 0.13-0.17) in CUD prevalence associated with RCLs, ie, 18.6% of the total increase in CUD prevalence in that age group. Conclusions and Relevance In this study of VHA patients, MCL and RCL enactment played a significant role in the overall increases in CUD prevalence, particularly in older patients. However, consistent with general population studies, effect sizes were relatively small, suggesting that cumulatively, laws affected cannabis attitudes diffusely across the country or that other factors played a larger role in the overall increases in adult CUD. Results underscore the need to screen for cannabis use and CUD and to treat CUD when it is present.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cannabis / Abuso de Maconha / Transtornos Relacionados ao Uso de Substâncias / Maconha Medicinal / Alucinógenos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cannabis / Abuso de Maconha / Transtornos Relacionados ao Uso de Substâncias / Maconha Medicinal / Alucinógenos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article